Oppelt, P.J.; Puram, S.V.; Liu, J.; Ley, J.C.; Adkins, D.
Tazemetostat, a Selective EZH2 Inhibitor, in Combination with Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 1 Trial. Cancers 2025, 17, 437.
https://doi.org/10.3390/cancers17030437
AMA Style
Oppelt PJ, Puram SV, Liu J, Ley JC, Adkins D.
Tazemetostat, a Selective EZH2 Inhibitor, in Combination with Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 1 Trial. Cancers. 2025; 17(3):437.
https://doi.org/10.3390/cancers17030437
Chicago/Turabian Style
Oppelt, Peter J., Sidharth V. Puram, Jingxia Liu, Jessica C. Ley, and Douglas Adkins.
2025. "Tazemetostat, a Selective EZH2 Inhibitor, in Combination with Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 1 Trial" Cancers 17, no. 3: 437.
https://doi.org/10.3390/cancers17030437
APA Style
Oppelt, P. J., Puram, S. V., Liu, J., Ley, J. C., & Adkins, D.
(2025). Tazemetostat, a Selective EZH2 Inhibitor, in Combination with Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 1 Trial. Cancers, 17(3), 437.
https://doi.org/10.3390/cancers17030437